Medicamen Biotech Ltd.

₹353.25

-1.9 (-0.5%)

MEDICAMEQ Share Price

Pharmaceuticals & Biotechnology

As on January 28, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 479 Cr

P/E Ratio68.51

Dividend Yield0.03 %

Trendline Performance

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	355.93	Bearish
10-DMA	364.84	Bearish
20-DMA	372.36	Bearish
50-DMA	385.19	Bearish
100-DMA	364.06	Bearish
200-DMA	387.42	Bearish

Historical Performance

1 Year

-19.8%

3 Years

-54.2%

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	1,625	1,793	1,409	1,154	1,127
Total Expenditure	1,481	1,558	1,165	914	930
Other Income	62	23	25	17	8
Operating Profit	207	258	268	258	204
Interest	37	57	34	19	15
Depreciation	71	71	64	58	25
Profit Before Tax	99	131	170	181	164
Consolidated Net Profit	66	95	147	149	121
Adjusted EPS	5	7	12	12	10

Compounded Sales Growth

10 Years:5.8

5 Years:5.3

3 Years:7.1

TTM:-1.9

Compounded Profit Growth

10 Years:-11.4

5 Years:-13.2

3 Years:-15.1

TTM:-7.1

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:-22.9

TTM:-22.1

Return on Equity

10 Years:N/A

5 Years:9.9

3 Years:11.6

last year:5.2

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	127	127	127	122	122
Total Reserves	2,003	1,943	1,782	1,343	1,207
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	31	5	7	60	78
Other Current Liabilities	15	111	73	50	49
Short Term Borrowings	295	296	233	193	109
Total Liabilities	2,943	2,920	2,766	2,252	1,940
Capital Work in Progress	---	---	---	---	---
Long Term Loans & Advances	12	12	11	9	8
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	271	278	297	87	114
Total Current Assets	1,645	1,596	1,634	1,230	960
Total Assets	2,943	2,920	2,766	2,252	1,940
Adjusted Book Value	162	158	145	114	103

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 68.51, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of -22.0%, indicating poor shareholder returns.
The stock carries a beta of 1.0, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹207 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹1625 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 779543.2

No. of Shares: 2207 (Approx)

Performance:-22%

P/L: ₹-220456.8

NIFTY Performance: 9.4%

1 day Top Gainers